Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of IMC-001 in advanced solid tumors
NCT03644056Phase 1Completed
- Sponsor
- ImmuneOncia Therapeutics, Inc.
- Start
- Mar 2018
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of danburstotug in solid tumor, sponsored by ImmuneOncia Therapeutics, Inc. Primary endpoint: Occurrence of Dose-Limiting Toxicities at 21 days. Started Mar 2018; status: completed.
02
Drugs
danburstotug
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03644056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03644056.